关于本次交易符合《上市公司监管指引第 9 号——上市公司 筹划和实施重大资产重组的监管要求》 昊华化工科技集团股份有限公司董事会 第四条规定的说明 昊华化工科技集团股份有限公司（以下简称"上市公司"、"公司"）拟向 中国中化集团有限公司（以下简称"中化集团"）发行股份购买其持有的中化蓝 天集团有限公司（以下简称"中化蓝天"）52.81%股权，向中化资产管理有限公 司（以下简称"中化资产"）发行股份购买其持有的中化蓝天 47.19%股权，并 向包括中国对外经济贸易信托有限公司和中化资本创新投资有限公司在内的不 超过 35 名符合条件的特定投资者非公开发行股份募集配套资金（以下简称"本 次交易"）。 公司董事会根据本次交易的实际情况作出审慎判断，认为本次交易符合《上 市公司监管指引第 9 号——上市公司筹划和实施重大资产重组的监管要求》第四 条的规定，具体如下： （1）公司本次交易中拟购买的标的资产中化蓝天 100%股权为股权类资产， 不涉及需要立项、环保、行业准入、用地、规划、建设施工等相关报批事项。本 次交易涉及的有关报批事项已在《昊华化工科技集团股份有限公司发行股份购买 资产并募集配套资金暨关联交易报告书（ ...

昊华化工科技集团股份有限公司董事会 关于本次交易符合《上市公司重大资产重组管理办法》 第十一条和第四十三条规定的说明 昊华化工科技集团股份有限公司（以下简称"上市公司"或"公司"）拟向中 国中化集团有限公司（以下简称"中化集团"）发行股份购买其持有的中化蓝天集 团有限公司（以下简称"中化蓝天"或"标的公司"）52.81%股权，向中化资产管 理有限公司（以下简称"中化资产"）发行股份购买其持有的中化蓝天 47.19%股权， 并向包含中国对外经济贸易信托有限公司（以下简称"外贸信托"）和中化资本创 新投资有限公司（以下简称"中化资本创投"）在内的不超过 35 名符合条件的特 定投资者非公开发行股份募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》的要求，公司董事会对本次交易是 否符合《上市公司重大资产重组管理办法》第十一条及第四十三条的规定进行了 审慎分析，认为： 一、本次交易符合《上市公司重大资产重组管理办法》第十一条的规定 6、本次交易有利于公司在业务、资产、财务、人员、机构等方面与实际控制 人及其关联人继续保持独立，符合中国证监会关于上市公司独立性的相关规定； 7、本次交易有利于公 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2023－041 昊华化工科技集团股份有限公司 第八届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昊华化工科技集团股份有限公司（以下简称"公司""上市公司" 或"昊华科技"）第八届董事会第六次会议于 2023 年 8 月 12 日在北 京市朝阳区小营路 19 号财富嘉园 A 座昊华大厦 19 层会议室以现场 结合视频通讯的方式召开，本次会议通知等材料已于 2023 年 8 月 9 日以电子邮件并短信通知的方式发送给公司董事、监事、高级管理人 员。会议应出席董事 9 名，实际出席董事 9 名，共收回有效表决票 9 份。会议由董事长胡冬晨先生主持，公司监事、高级管理人员等列席 会议。会议的召开符合相关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定。 会议审议并通过如下议案： 一、关于审议公司发行股份购买资产并募集配套资金暨关联交 易符合相关条件的议案 公司拟以发行股份的方式购买中国中化集团有限公司（以下简称 "中化集团"）、中化资产 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2023-048 昊华化工科技集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 23 日（星期三）至 8 月 29 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 hhkj@sinochem.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 昊华化工科技集团股份有限公司（以下简称"公司"）将于 2023 年 8 月 26 日在《中国证券报》《上海证券报》和上海证券交易所网站 披露《昊华科技 2023 年半年度报告》，为便于广大投资者更全面深入 地了解公司情况，公司将于 2023 年 8 月 30 日（星期三）下午 14:00-15:00 召开 2023 年半年度业绩说明会，现将有关事项公告如下： ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2023-040 昊华化工科技集团股份有限公司 关于重大资产重组的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司因筹划发行股份购买资产并募集配套资金事项，根据有关规定，经公司 向上海证券交易所申请，公司股票于 2023 年 2 月 1 日（星期三）开市起停牌。 具体内容详见公司披露的《昊华化工科技集团股份有限公司关于筹划重大资产重 组事项的停牌公告》（编号：临 2023-006）。 在停牌期间，公司根据相关规定发布了停牌进展公告。具体内容详见公司于 2023 年 2 月 8 日披露的《昊华化工科技集团股份有限公司关于筹划重大资产重 组事项的停牌进展公告》（编号：临 2023-011）。 2023 年 2 月 14 日，公司召开第八届董事会第二次会议，审议通过了《昊华 化工科技集团股份有限公司发行股份购买资产并募集配套资金暨关联交易方案 的议案》《关于<昊华化工科技集团股份有限公司发行股份购买资产并募集配套 资金暨关联交易预案>及摘要的议案》等相关议案。具 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2023-031 会议召开方式：现场交流、视频直播和网络文字互动 问题征集：投资者可于 5 月 11 日(星期四)16:00 前登录上证路演中心网 站首页点击"提问预征集"栏目或通过公司邮箱 hhkj@sinochem.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 昊华化工科技集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日和 2023 年 4 月 29 日发布《昊华科技 2022 年年度报告》和《昊华科技 2023 年第一季度报告》。为便于广大投资者更全面、更深入地了解中国中化控股有限 责任公司（以下简称"中国中化"）所属上市公司，同时以更为丰富、便捷的形 式与投资者进行交流和互动，根据中国中化统一安排，公司将与中国中化所属的 其他 6 家上交所上市公司于 2023 年 5 月 12 日（星期五）下午共同参加集体业绩 说明会。 一、 说明会类型 本次会议系中国中化举办的首次集体业绩说明会，旨在加强与投资者沟通， 推进上市公司高质量发展，向市场充分展现中国中化控股上市公司的业务发展价 昊华化工科技集团股份 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,057,715,959.56, representing an increase of 11.01% compared to ¥1,853,635,236.31 in the same period last year[4] - Net profit attributable to shareholders was ¥227,820,566.77, a slight increase of 2.37% from ¥222,536,455.34 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥224,850,996.92, up by 1.84% from ¥220,796,096.39 year-on-year[5] - Basic and diluted earnings per share were both ¥0.2521, reflecting a 1.57% increase from ¥0.2482 in the previous year[5] - Total revenue for Q1 2023 reached ¥2,057,715,959.56, an increase of 11.0% compared to ¥1,853,635,236.31 in Q1 2022[21] - Total operating costs for Q1 2023 were ¥1,864,979,386.82, up from ¥1,665,150,382.78 in Q1 2022, reflecting a year-over-year increase of 12.0%[21] - The total profit for Q1 2023 was CNY 249,624,947.78, compared to CNY 246,169,363.94 in Q1 2022, representing a growth of about 1.0%[22] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of ¥49,739,204.36, worsening from a net outflow of ¥25,475,435.38 in the same period last year[5] - Current assets decreased to ¥7,973,408,806.97 in Q1 2023 from ¥8,551,279,776.96 in Q4 2022, a decline of 6.7%[18] - Total assets at the end of the reporting period were ¥14,888,621,752.74, down by 3.48% from ¥15,424,906,958.66 at the end of the previous year[5] - Cash and cash equivalents decreased to ¥2,355,381,825.75 in Q1 2023 from ¥2,689,201,101.39 in Q4 2022, a decline of 12.4%[18] - The net cash flow from operating activities for Q1 2023 was -CNY 49,739,204.36, worsening from -CNY 25,474,128.56 in Q1 2022[25] - The net cash flow from investing activities for Q1 2023 was -CNY 201,916,778.74, an improvement from -CNY 356,756,001.94 in Q1 2022[25] - The company experienced a net cash outflow from financing activities of -CNY 67,496,984.35 in Q1 2023, compared to a net inflow of CNY 156,830,068.08 in Q1 2022[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,788[9] - The controlling shareholder, China Haohua Chemical Group Co., Ltd., holds 590,198,123 shares, representing 64.75% of the total shares[10] - The top ten shareholders hold a combined total of 843,000,000 shares, accounting for approximately 93.5% of the total shares[11] - As of March 31, 2023, Yingtou Holdings Co., Ltd. holds 36,306,800 shares, with a pledge on 27,200,000 shares[10] Asset Restructuring and Corporate Actions - The company is undergoing a major asset restructuring to acquire 100% equity of Sinochem Blue Sky Group Co., Ltd., which is expected to constitute a significant asset restructuring and related party transaction[14] - The company’s stock was suspended from trading on February 1, 2023, due to the planned major asset restructuring[14] - The company’s stock resumed trading on February 15, 2023, following the completion of the necessary disclosures related to the asset restructuring[15] - The company is actively progressing with the asset acquisition, with ongoing audits and evaluations yet to be completed[15] Financial Position and Equity - Total assets amounted to ¥14,888,621,752.74 in Q1 2023, down from ¥15,424,906,958.66 in Q4 2022, representing a decrease of 3.5%[20] - Current liabilities decreased to ¥4,023,904,778.73 in Q1 2023 from ¥5,046,712,339.65 in Q4 2022, a reduction of 20.2%[19] - Non-current liabilities increased to ¥2,396,153,283.78 in Q1 2023 from ¥2,154,956,461.37 in Q4 2022, an increase of 11.2%[20] - Shareholders' equity attributable to the parent company increased to ¥8,445,815,295.75, a growth of 3.00% from ¥8,200,195,429.26 year-on-year[5] - Shareholders' equity rose to ¥8,468,563,690.23 in Q1 2023, compared to ¥8,223,238,157.64 in Q4 2022, reflecting an increase of 3.0%[20] Judicial and Regulatory Matters - The company reported a judicial freeze on a total of 24,366,612 shares held by its controlling shareholder, with various court orders in effect until late 2024[12][13] - The company has not disclosed any significant changes in its financial audit opinion for the first quarter of 2023[17] Research and Development - Research and development expenses for Q1 2023 amounted to CNY 135,277,270.04, slightly up from CNY 133,009,846.04 in Q1 2022[22]

Financial Performance - The company achieved a net profit attributable to shareholders of 1,164,886,425.27 yuan for the year 2022, with a total distributable profit of 4,455,130,492.94 yuan[3]. - The company's operating revenue for 2022 was ¥9,067,529,684.27, representing a 22.13% increase compared to ¥7,424,354,099.10 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥1,164,886,425.27, a 30.67% increase from ¥891,462,415.27 in 2021[17]. - The net cash flow from operating activities for 2022 was ¥993,840,073.13, a decrease of 13.31% compared to ¥1,146,408,768.22 in 2021[17]. - The total assets at the end of 2022 were ¥15,424,906,958.66, reflecting a 32.30% increase from ¥11,658,860,394.51 at the end of 2021[17]. - The basic earnings per share for 2022 was ¥1.2872, up 30.28% from ¥0.9880 in 2021[18]. - The weighted average return on equity for 2022 was 15.16%, an increase of 2.02 percentage points from 13.14% in 2021[18]. - The company reported non-recurring gains of ¥201,177,921.84 for 2022, compared to ¥7,341,057.27 in 2021[22]. Dividend Policy - A cash dividend of 6.40 yuan per 10 shares (including tax) will be distributed to all shareholders, totaling 583,343,236.48 yuan (including tax), which represents 50.08% of the net profit attributable to shareholders[3]. - The company maintains a stable dividend policy while considering operational funding needs[3]. - The company has a cash dividend policy that requires at least 10% of the net profit attributable to shareholders to be distributed as cash dividends each year[193]. - The company has a policy to cumulatively distribute at least 30% of the average annual net profit attributable to shareholders over any three consecutive fiscal years[193]. - The company emphasizes the importance of maintaining a stable and continuous profit distribution policy to ensure reasonable returns for investors while considering sustainable development[193]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[4]. - The company has established safety and environmental management systems to mitigate risks associated with hazardous chemicals and is committed to improving safety management levels[136]. - The company faces customer credit risks related to accounts receivable and has implemented dynamic management strategies to ensure timely collection of payments[137]. Research and Development - Research and development expenses amounted to 726 million RMB, reflecting a year-on-year increase of 17.2%[26]. - The company has established a youth technology talent pool to enhance its workforce and management capabilities[29]. - The company has undertaken a total of 210 research projects during the reporting period, including 44 national-level projects and 139 key projects independently developed by the company[83]. - The company applied for 317 patents in 2022, with 240 being domestic invention patents, and received 210 domestic patent authorizations, including 120 domestic invention patents[84]. - The company is actively involved in the research and development of new technologies and products, focusing on key core technologies[85]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[23]. - The company is actively expanding its market presence in the fluorochemical and electronic chemical industries, leveraging its resource advantages[30]. - The company aims to achieve significant breakthroughs in key core technologies by 2035 as part of its strategy to drive domestic demand and innovation[78]. - The company plans to enhance market development and business collaboration, focusing on optimizing pricing mechanisms and improving product structure[122]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the chemical sector[155]. Corporate Governance - All board members attended the board meeting, ensuring the integrity of the annual report[2]. - The company has established a comprehensive internal control system to ensure risk management and compliance with regulatory requirements[143]. - The company has revised its governance structure and management systems to align with the "14th Five-Year Plan" and investment management guidelines[140]. - The company held 5 shareholder meetings, 14 board meetings, and 7 supervisory board meetings during the reporting period, complying with the requirements of the Articles of Association[139]. - The company has enhanced its investor relations management system to improve transparency and communication with stakeholders[141]. Financial Health and Investments - Operating costs increased by 26.98% to CNY 6.86 billion, primarily due to rising prices of chemical raw materials[55]. - The net cash flow from investing activities saw a significant decline of 85.88%, mainly due to increased project construction investment[55]. - The company reported a total investment in equity of CNY 194,769.33 million, with an increase of CNY 46,504.48 million during the reporting period[112]. - The company has a total of 562,800 shares held at the end of the reporting period, down from 840,000 shares at the beginning[154]. - The company reported a significant increase in revenue, achieving a total of 61 billion RMB for the year 2022[155]. Leadership and Management Changes - The company reported a significant leadership change with the resignation of independent directors after their six-year term, which will take effect after the election of new independent directors[157]. - The company appointed Li Shu and Zhao Huailiang as independent director candidates for the seventh board, following the resignation of independent directors Shen Chang'e and Xu Junli due to term expiration[158]. - The company held its first extraordinary general meeting of 2023 on February 2, where it elected members for the eighth board, including Hu Dongchen as chairman and Wang Jun as vice chairman[162]. - The company has a strategic execution department director appointed in November 2022, indicating a focus on strategic initiatives[168]. - The company has a focus on research and development, with key personnel involved in various scientific and technological roles[168].